Ginsburg Drugs And Formulations Private Limited, a active private limited company, was established on 11 October 2004 in Gorakhpur, Uttar Pradesh, India. Engaging in medical equipment retail & distribution within the trade sector, it holds CIN: U24232UP2004PTC029153. Registered under ROC Roc Kanpur. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹1.00 M.
It upholds a compliant status. Its leadership includes Avnish Rao (Director), Vasu Vinayak Rao (Director), Shanti Bhushan Rao (Director). Past directors included Umesh Pratap Rao, Shri Narayan Rao, Kanti Devi Rao. It holds ₹5.10 M open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 229-Q Ground Floor Nh-28 Near Deoria By Pass Daudpur, Gorakhpur, Uttar Pradesh, 273016.
U24232UP2004PTC029153
029153
11 October 2004
₹1.00 M
₹1.00 M
Roc Kanpur
Unlisted
Active
Explore comprehensive insights into Ginsburg Drugs And Formulations Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Avnish Rao | Director | 19 Jan 2024 | Current |
| Vasu Vinayak Rao | Director | 24 Feb 2024 | Current |
| Shanti Bhushan Rao | Director | 11 Oct 2004 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 29 Feb 2024 | Past |
| Pramod Abcsdd | Director | 04 Apr 2014 | Past |
| Pramod Abcsdd | Director | 16 Jan 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Ginsburg Drugs And Formulations Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 9.9% increase. The company also saw a slight improvement in profitability, with a 3.59% increase in profit. The company's net worth moved up by a moderate rise of 6.55%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2017, Ginsburg Drugs And Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹5,095,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Jul 2020 | Others | ₹3.60 M | Open |
| 28 Feb 2013 | Allahabd Bank | ₹1.50 M | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Ginsburg Drugs And Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Ginsburg Drugs And Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ginsburg Drugs And Formulations's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Ginsburg Drugs And Formulations Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Progress on Ginsburg Drugs And Formulations Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Kanpur. was documented.
Vasu Vinayak Rao was appointed as a Director was appointed as a Director on 24 Feb 2024 & has been associated with this company since 1 year 9 months . was recorded as a recent event.
The activity Avnish Rao was appointed as a Director was appointed as a Director on 19 Jan 2024 & has been associated with this company since 1 year 10 months . was completed.
The activity A charge with Others amounted to Rs. 3.60 M with Charge ID 100368631 was registered on 03 Jul 2020. was completed.
The activity A charge with Allahabd Bank amounted to Rs. 1.50 M with Charge ID 10413396 was registered on 28 Feb 2013. was completed.
The CIN of Ginsburg Drugs And Formulations Private Limited is U24232UP2004PTC029153.
Ginsburg Drugs And Formulations Private Limited is headquartered at 229-Q Ground Floor Nh-28 Near Deoria By Pass Daudpur, Gorakhpur, Uttar Pradesh, 273016.
Ginsburg Drugs And Formulations Private Limited was incorporated on 11 October 2004.
The current directors of Ginsburg Drugs And Formulations Private Limited are
The primary industry of Ginsburg Drugs And Formulations Private Limited is Trade.
Ginsburg Drugs And Formulations Private Limited is unlisted.
The authorized capital of Ginsburg Drugs And Formulations Private Limited is ₹1.00 M, and the paid-up capital is ₹1.00 M.
The compliance status of Ginsburg Drugs And Formulations Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX